R Squared’s Esperion Therapeutics ESPR Stock Holding History

R Squared’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,173	Closed	-$56.1K	–	550
2025 Q4	$56.1K	Buy	15,173 +2,890	+24%	+$9.34K	0.03%	450
2025 Q3	$32.5K	Buy	+12,283	New	+$23.8K	0.01%	517

Other funds holding ESPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

R Squared's ESPR Position: Q1 2026 in Review

R Squared sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 15,173 shares — an estimated $56.1K sold.

R Squared first reported a position in ESPR in Q3 2025 and held it in 2 quarters. The position peaked at $56.1K in Q4 2025. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

R Squared reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
R Squared sold 15,173 Esperion Therapeutics shares in Q1 2026, an estimated $56.1K.
R Squared first reported a position in Esperion Therapeutics in Q3 2025 and held it in 2 quarters.
R Squared's Esperion Therapeutics position peaked at $56.1K in Q4 2025.
207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.